Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors
Open Access
- 3 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 26 (10), 2233-2244
- https://doi.org/10.1038/leu.2012.96
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Survey of Activated FLT3 Signaling in LeukemiaPLOS ONE, 2011
- Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity ComparisonGenes & Cancer, 2010
- Antitumor Activity of Targeting Src Kinases in Endothelial and Myeloid Cell Compartments of the Tumor MicroenvironmentClinical Cancer Research, 2010
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood, 2009
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapyBlood, 2009
- Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cellsLeukemia, 2008
- Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cellsBlood, 2008
- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemiaBlood, 2006
- Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDBlood, 2006
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004